Boston Scientific studies show benefits of SCS devices

Boston Scientific has presented new clinical data from a pair of studies showcasing the benefits of two of its spinal cord stimulation (SCS) devices.

Addressing attendees at the International Spine Intervention Society's annual meeting, the company offered data from a study of its Infinion 16 Percutaneous Lead, demonstrating its ability to provide significant pain relief in patients with chronic pain.

The device is the world's first and only 16-contact percutaneous lead for SCS therapy and is designed for use in conjunction with the Precision Plus SCS System.

Meanwhile, data from a second study showcased the ability of its Clik Anchor fixation device to reduce lead migration, the most common complication associated with SCS therapy.

Maulik Nanavaty, senior vice-president and president of the neuromodulation division at Boston Scientific, said: "The Infinion 16 Lead and Clik Anchor studies underscore our commitment to developing industry-leading technologies that advance the management of chronic pain and mitigate difficulties associated with SCS therapy."

This comes after the firm completed enrolment for a new trial of the left atrial appendage closure device Watchman earlier this month.